NCT06351332 2026-01-12ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCDana-Farber Cancer InstitutePhase 1/2 Active not recruiting78 enrolled
NCT04673448 2026-01-09Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerUniversity of WashingtonPhase 1 Active not recruiting18 enrolled
NCT01552434 2025-10-14Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign DiseaseM.D. Anderson Cancer CenterPhase 1 Active not recruiting155 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT03644589 2019-04-26Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast CancerUniversity of WashingtonPhase 2 Withdrawn